Evoke Pharma Return on Tangible Equity 2012-2025 | EVOK
Current and historical return on tangible equity values for Evoke Pharma (EVOK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Evoke Pharma Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-09-30 | $-0.01B | $0.01B | -100.00% |
| 2025-06-30 | $-0.01B | $0.01B | -95.24% |
| 2025-03-31 | $0.00B | $0.01B | -80.00% |
| 2024-12-31 | $-0.01B | $0.00B | -117.65% |
| 2024-09-30 | $-0.01B | $0.00B | -342.86% |
| 2024-06-30 | $-0.01B | $0.00B | -1400.00% |
| 2024-03-31 | $-0.01B | 0 | 0.00% |
| 2023-12-31 | $-0.01B | -0 | 3200.00% |
| 2023-09-30 | $-0.01B | $0.00B | -533.33% |
| 2023-06-30 | $-0.01B | $0.00B | -246.15% |
| 2023-03-31 | $-0.01B | $0.01B | -168.42% |
| 2022-12-31 | $-0.01B | $0.01B | -168.42% |
| 2022-09-30 | $-0.01B | $0.01B | -168.42% |
| 2022-06-30 | $-0.01B | $0.01B | -177.78% |
| 2022-03-31 | $-0.01B | $0.00B | -188.24% |
| 2021-12-31 | $-0.01B | $0.01B | -156.52% |
| 2021-09-30 | $-0.01B | $0.00B | -225.00% |
| 2021-06-30 | $-0.01B | $0.00B | -400.00% |
| 2021-03-31 | $-0.01B | $0.00B | -1866.67% |
| 2020-12-31 | $-0.01B | $0.00B | 2600.00% |
| 2020-09-30 | $-0.01B | $0.00B | -960.00% |
| 2020-06-30 | $-0.01B | $0.00B | -400.00% |
| 2020-03-31 | $-0.01B | $0.01B | -155.56% |
| 2019-12-31 | $-0.01B | $0.01B | -155.56% |
| 2019-09-30 | $-0.01B | $0.01B | -177.78% |
| 2019-06-30 | $-0.01B | $0.01B | -177.78% |
| 2019-03-31 | $-0.01B | $0.00B | -188.24% |
| 2018-12-31 | $-0.01B | $0.01B | -177.78% |
| 2018-09-30 | $-0.01B | $0.00B | -150.00% |
| 2018-06-30 | $-0.01B | $0.00B | -276.92% |
| 2018-03-31 | $-0.01B | $0.00B | -240.00% |
| 2017-12-31 | $-0.01B | $0.01B | -252.63% |
| 2017-09-30 | $-0.01B | $0.01B | -266.67% |
| 2017-06-30 | $-0.01B | $0.01B | -200.00% |
| 2017-03-31 | $-0.01B | $0.00B | -346.67% |
| 2016-12-31 | $-0.01B | $0.00B | -550.00% |
| 2016-09-30 | $-0.01B | $0.00B | -685.71% |
| 2016-06-30 | $-0.01B | $0.00B | -685.71% |
| 2016-03-31 | $-0.01B | $0.00B | -369.23% |
| 2015-12-31 | $-0.01B | $0.01B | -288.89% |
| 2015-09-30 | $-0.01B | $0.01B | -216.67% |
| 2015-06-30 | $-0.01B | $0.01B | -180.65% |
| 2015-03-31 | $-0.02B | $0.01B | -142.86% |
| 2014-12-31 | $-0.01B | $0.01B | -103.70% |
| 2014-09-30 | $-0.01B | $0.02B | -78.79% |
| 2014-06-30 | $-0.01B | $0.02B | -49.32% |
| 2014-03-31 | $-0.01B | $0.01B | -35.71% |
| 2013-12-31 | $0.00B | $0.01B | -21.05% |
| 2013-06-30 | $0.00B | $0.00B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |